JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer

Abstract CDK4/6 inhibitors in combination with endocrine therapy are now used as front-line treatment for patients with estrogen-receptor positive (ER+) breast cancer. While this combination improves overall survival, the mechanisms of disease progression remain poorly understood. Here, we performed...

Cijeli opis

Bibliografski detalji

Glavni autori:	Sarah Alexandrou, Christine S. Lee, Kristine J. Fernandez, Celine E. Wiharja, Leila Eshraghi, John Reeves, Daniel A. Reed, Neil Portman, Zoe Phan, Heloisa H. Milioli, Iva Nikolic, Antonia L. Cadell, David R. Croucher, Kaylene J. Simpson, Elgene Lim, Theresa E. Hickey, Ewan K. A. Millar, Carla L. Alves, Henrik J. Ditzel, C. Elizabeth Caldon
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2025-08-01
Serija:	Journal of Experimental & Clinical Cancer Research
Teme:	CDK4/6 inhibition Palbociclib ER+ breast cancer JNK signalling Endocrine therapy
Online pristup:	https://doi.org/10.1186/s13046-025-03466-9
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!